This book is based on several years of research, and it is also a field study of biopharma strategy through the value chain, including many executive interviews and company case studies. We benefited as well from management seminars and academic executive programs that allowed us to test our models and concepts.

A global network of academic and industry leaders brought great value to our book. At the risk of overlooking several, we first note the experts and executives who contributed thoughtful comments and case studies: Philip Kotler, whose seminal work in healthcare strategy inspired us, and Charlotte Sibley (former SVP, Shire), who generously provided in-depth reviews and expert insights throughout our book; Olivier Brandicourt (Board Member, PhRMA), Roch Doliveux (former CEO, UCB), Wendy Gabel (former VP, Biogen), and Bernard Poussot (Board Member, Roche) also provided valuable comments.

John Maraganore (CEO Alnylam), Michael Pehl (President, Hematology and Oncology, Celgene), and Jacqualyn Fouse (Executive Chair, Dermavant and retired President and COO, Celgene), as well as Emmanuel Blin (former SVP, Bristol-Myers Squibb) contributed company case studies.

In Europe, we benefited from a case study from Maryvonne Hiance, Dominique Costantini, and Emile Loria at OSE Immunotherapeutics, and thoughtful reviews and insights from Philippe Latapie, François Meurgey, and Catherine Parisot.

Françoise Simon would also like to extend her appreciation to her academic colleagues: At the Icahn School of Medicine at Mount Sinai, Dean Dennis Charney; Annetine Gelijns, Professor and System Chair, Population Health Science and Policy; and Senior Associate Dean, Brian Nickerson, for their support, and Dr. Bruce Darrow, Mount Sinai Chief Medical Information Officer, for his technology expertise.

At Columbia, Françoise Simon would like to acknowledge Deans Linda Fried at the Mailman School of Public Health and Glenn Hubbard at the Business School, and she thanks Professors Kamel Jedidi, Don Lehmann, and Michael Sparer for their support, as well as Emerita Professor Marianne Legato for sharing her expertise in gender-based medicine; in Europe, she thanks Professors Nathalie Angelé-Halgand and Frantz Rowe at the Université de Nantes, Martine Bellanger at EHESP, Claire Champenois at Audencia, Pierre Lévy at Université Paris-Dauphine, and Christine Coisne and Loïc Menvielle at EDHEC for providing an academic testing ground for the book.

At INSEAD, Françoise Simon also thanks Professor Stephen Chick and Research Program Manager Ridhima Aggarwal for the use of the PatientsLikeMe case, which she co-wrote with them and excerpted in the book.

Both authors give a special acknowledgement to Ellen Licking, Senior Life Sciences Analyst at EY, for her insights, her network and for her research and editorial contributions. Ellen worked with great dedication to advance the research for the entire book, with particular emphasis on the following areas: precision medicine, data analytics, new pricing models, and strategic payer engagement.

In addition to Ellen, Glen Giovannetti would like to thank many colleagues at EY including Global Life Sciences Sector Leader Pamela Spence, Susan Garfield, Kristin Pothier, and Ryan Juntado for their contributed articles. EY Life Sciences specialists Jeff Greene, Scott Palmer, Mahala Burn, Alan Kalton, Todd Skrinar, Jamie Hintlian, and Adlai Goldberg also provided invaluable insights. Melanie Senior, a life sciences writer and analyst, provided support for the precision medicine and payer engagement sections of the book. Jason Hillenbach and Rajni Sadana ably led a research team who also provided support for many of the figures in the book, and Angela Kyn provided marketing support.

Finally, we would like to thank our publisher, John Wiley & Sons, and our editor, Bob Esposito, and Editorial Director, Justin Jeffryes, for their expert guidance through our book.